Stock Analysis
Lavipharm (ATH:LAVI) First Quarter 2024 Results
Key Financial Results
- Revenue: €13.2m (down 4.6% from 1Q 2023).
- Net income: €780.0k (up 32% from 1Q 2023).
- Profit margin: 5.9% (up from 4.3% in 1Q 2023).
- EPS: €0.005.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Lavipharm shares are down 4.1% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Lavipharm (at least 1 which makes us a bit uncomfortable), and understanding these should be part of your investment process.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ATSE:LAVI
Lavipharm
Engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, dermocosmetic, and healthcare products to physicians and pharmacists in Greece and internationally.
